| All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) HJ Iland, K Bradstock, SG Supple, A Catalano, M Collins, M Hertzberg, ... Blood, The Journal of the American Society of Hematology 120 (8), 1570-1580, 2012 | 342 | 2012 |
| Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study … HJ Iland, M Collins, K Bradstock, SG Supple, A Catalano, M Hertzberg, ... The Lancet Haematology 2 (9), e357-e366, 2015 | 161 | 2015 |
| Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4) HJ Iland, K Bradstock, SG Supple, A Catalano, M Collins, M Hertzberg, ... Blood 120 (8), 1570-80, 2012 | 59 | 2012 |
| Australasian Leukaemia and Lymphoma Group. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian … HJ Iland, M Collins, K Bradstock, SG Supple, A Catalano, M Hertzberg, ... Lancet Haematol 2 (9), e357-e366, 2015 | 24 | 2015 |
| Quality of life in patients with pulmonary embolism treated with edoxaban versus warfarin R Bavalia, IM Bistervels, WG Boersma, I Quere, D Brisot, N Falvo, ... Research and practice in thrombosis and haemostasis 5 (5), e12566, 2021 | 5 | 2021 |
| Direct oral anticoagulants or vitamin K antagonists in emergencies: comparison of management in an observational study RI Baker, G Gilmore, V Chen, L Young, E Merriman, J Curnow, J Joseph, ... Research and practice in thrombosis and haemostasis 7 (5), 100196, 2023 | 3 | 2023 |
| Postthrombotic syndrome and quality of life after deep vein thrombosis in patients treated with edoxaban versus warfarin IM Bistervels, R Bavalia, J Beyer‐Westendorf, AJ ten Cate‐Hoek, ... Research and practice in thrombosis and haemostasis 6 (5), e12748, 2022 | 3 | 2022 |
| Treatment options for major haemorrhage and urgent intervention in patients on a NOAC-interim results from the anticoagulation reversal and events study (ARES) collaborative R Baker, A Gallus, T Brighton, P Harper, L Young, J Joseph, A Hugman, ... JOURNAL OF THROMBOSIS AND HAEMOSTASIS 13, 643-643, 2015 | 1 | 2015 |
| Triple Therapy For Immune Thrombocytopenia: A Novel Combination Of Conventional Strategies To Safely Sustain Platelet Counts In ITP PYI Choi, SC Ng, C Lee, F Roncolato, X Badoux, AJ Hugman, ... Blood 122 (21), 1084, 2013 | 1 | 2013 |
| Hokusai post-PE study: a follow-up study on long-term outcomes of pulmonary embolism in patients treated with edoxaban vs warfarin I Bistervels, W Boersma, R Bavalia, K Meijer, P Verhamme, H Ten Cate, ... European Respiratory Journal 56 (suppl 64), 2020 | | 2020 |
| All-trans-retinoic acid, idarubicin, and arsenic therapy for APL HJ Iland, K Bradstock, SG Supple, A Catalano, M Collins, M Hertzberg, ... Blood 120 (8), 2012 | | 2012 |
| Development of a real-time semi-quantitative assay for JAK2 V617F mutation with case studies L Lee, C Paul, A Hugman, L Coyle, H Iland INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY 30, 123-123, 2008 | | 2008 |
